Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilars

Set Alert for Biosimilars

What’s Next? Five Things To Look Out For In October

A busy October will include planned biosimilar launches and key appointments for the off-patent sector.

Generic Drugs Biosimilars

Sandoz: Big Cap Biosimilar Rivals Lack Clarity On Commitment

Sandoz has had its say on its biosimilar rivals with largely branded portfolios, as well as the recent EMA statement supporting biosimilar interchangeability.

Biosimilars Strategy

What Aspects Will Give Humira Biosimilars The Edge In 2023?

With multiple Humira biosimilars slated for launch in the US next year, some simultaneously, a Vizient survey provides some insights into what could be the most important differentiating aspects. Generics Bulletin speaks to Steven Lucio, Vizient senior principal of pharmacy solutions, about the findings.

Biosimilars Market Intelligence

US Patients Continue To Overpay For Off-Patent Drugs Despite $373bn In Savings

The US Association for Accessible Medicines’ annual report into generic and biosimilar savings has documented another year of increased cost savings thanks to off-patent drugs, but says some patients are still overpaying for their generic medicines. 

Generic Drugs Biosimilars

Shortlist Unveiled For GGB Awards

The final shortlist of contenders has been unveiled for the Global Generics & Biosimilars Awards 2022, which returns to Frankfurt on 2 November.

Generic Drugs Biosimilars

Prestige Pulls Trastuzumab After EMA Knockback

Prestige Biopharma has formally withdrawn its marketing authorization application for its Tuznue (trastuzumab) biosimilar candidate, following a negative opinion from the EMA’s CHMP as well as a requested re-examination.

Biosimilars Europe

Formycon Reveals Keytruda Biosimilar In The Works

Formycon has revealed that pembrolizumab is one of its six biosimilars in development. The blockbuster reference biologic Keytruda brought in $17.2bn for Merck & Co. in 2021.

Biosimilars Strategy

Sandoz Delivers Denosumab Data As Biogen Sues On Tysabri

Having previously identified itself as the frontrunner in the race to launch a biosimilar to Amgen’s Prolia, Sandoz has now delivered positive confirmatory data, shortly after being sued in the US over its Polpharma-partnered proposed Tysabri biosimilar.

Biosimilars Clinical Trials

EMA And HMA Speak Out In Favor Of Biosimilar Interchangeability

Stakeholders in Europe have been hesitant to allow interchangeable substitution of biological products, prompting the European Medicines Agency to clarify its stance on the issue.

Biosimilars Europe
See All
UsernamePublicRestriction

Register